Search

Search Results

1. Assessment of cerebral drug occupancy in humans using a single PET-scan: A [¹¹C]UCB-J PET study

   Purpose

   Here, we evaluate a PET displacement model with a Single-step and Numerical solution in healthy individuals using the synaptic vesicle...

   Maja R. Marstrand-Joergensen, Gjertrud L. Laurell, ... Lars H. Pinborg in European Journal of Nuclear Medicine and Molecular Imaging

   Article Open access 17 May 2024
   

2. Drug characteristics derived from kinetic modeling: combined ¹¹C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A

   Background

   Antiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure...

   Mika Naganawa, Jean-Dominique Gallezot, ... Richard E. Carson in EJNMMI Research

   Article Open access 08 November 2022
   

3. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [¹¹C]UCB-J

   Purpose

   Aging is a major societal concern due to age-related functional losses. Synapses are crucial components of neural circuits, and synaptic...

   Takuya Toyonaga, Nikkita Khattar, ... Richard E. Carson in European Journal of Nuclear Medicine and Molecular Imaging

   Article 13 November 2023
   

4. Validation and test–retest repeatability performance of parametric methods for [¹¹C]UCB-J PET

   [ ¹¹ C]UCB-J is a PET radioligand that binds to the presynaptic vesicle glycoprotein 2A. Therefore, [ ¹¹ C]UCB-J PET may serve as an in vivo marker of...

   Hayel Tuncel, Ronald Boellaard, ... Sandeep S. V. Golla in EJNMMI Research

   Article Open access 24 January 2022
   

5. Feasibility of imaging synaptic density in the human spinal cord using [¹¹C]UCB-J PET

   Purpose

   Neuronal damage and synapse loss in the spinal cord (SC) have been implicated in spinal cord injury (SCI) and neurodegenerative disorders such...

   Samantha Rossano, Takuya Toyonaga, ... Richard E. Carson in EJNMMI Physics

   Article Open access 03 May 2022
   

6. Human biodistribution and dosimetry of [¹¹C]-UCB-J, a PET radiotracer for imaging synaptic density

   Rationale

   [ ¹¹ C]-UCB-J is an emerging tool for the noninvasive measurement of synaptic vesicle density in vivo. Here, we report human biodistribution...

   Christopher Cawthorne, Paul Maguire, ... Michel Koole in EJNMMI Physics

   Article Open access 23 April 2021
   

7. Preclinical PET Studies of [¹¹C]UCB-J Binding in Minipig Brain

   Purpose

   Loss of neuronal synapse function is associated with a number of brain disorders. The [ ¹¹ C]UCB-J positron emission tomography (PET) tracer...

   Majken Borup Thomsen, Anna Christina Schacht, ... Anne M. Landau in Molecular Imaging and Biology

   Article 08 June 2020
   

8. Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [¹¹C]UCB-J PET study in a model of obsessive–compulsive disorder-like behaviour

   Background

   Currently, the evidence on synaptic abnormalities in neuropsychiatric disorders—including obsessive–compulsive disorder (OCD)—is emerging....

   Dorien Glorie, Jeroen Verhaeghe, ... Steven Staelens in EJNMMI Research

   Article Open access 13 November 2020
   

9. ¹¹C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies

   Objective

   Dementia with Lewy bodies (DLB) is a common cause of dementia, but atrophy is mild compared to Alzheimer’s disease. We propose that DLB is...

   Nicolas Nicastro, Negin Holland, ... John T. O’Brien in European Journal of Hybrid Imaging

   Article Open access 22 December 2020
   

10. Improved synthesis of SV2A targeting radiotracer [¹¹C]UCB-J

    Introduction

    [ ¹¹ C]UCB-J is a tracer developed for PET (positron emission tomography) that has high affinity towards synaptic vesicle glycoprotein 2A...

    Johanna Rokka, Eva Schlein, Jonas Eriksson in EJNMMI Radiopharmacy and Chemistry

    Article Open access 29 November 2019

11. Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand ¹¹C-UCB-J

    Abstract

    The ability to quantify synaptic density in vivo in human adults and adolescents is of vital importance to understanding neuropsychiatric...

    Jason Bini, Daniel Holden, ... Richard E. Carson in EJNMMI Research

    Article Open access 14 July 2020
    

12. Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial

    Selective serotonin reuptake inhibitors (SSRIs) are widely used for treating neuropsychiatric disorders. However, the exact mechanism of action and...

    Annette Johansen, Sophia Armand, ... Gitte M. Knudsen in Molecular Psychiatry

    Article Open access 09 October 2023
    

13. In vivo evidence of lower synaptic vesicle density in schizophrenia

    Decreased synaptic spine density has been the most consistently reported postmortem finding in schizophrenia (SCZ). A recently developed in vivo...

    Rajiv Radhakrishnan, Patrick D. Skosnik, ... Deepak C. D’Souza in Molecular Psychiatry

    Article 16 June 2021
    

14. The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study

    Glutamatergic excitotoxicity is hypothesised to underlie synaptic loss in schizophrenia pathogenesis, but it is unknown whether synaptic markers are...

    Ellis Chika Onwordi, Thomas Whitehurst, ... Oliver D. Howes in Translational Psychiatry

    Article Open access 17 July 2021
    

15. Validation of Parametric Methods for [¹¹C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue

    Purpose

    The aim of this study was to evaluate different non-invasive methods for generating (R)-1-((3-([ ¹¹ C]methyl)pyridin-4-yl)methyl)-4-(3,4,5-trifl...

    Nathalie Mertens, Ralph Paul Maguire, ... Michel Koole in Molecular Imaging and Biology

    Article 17 June 2019
    

16. Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern

    Next to amyloid and tau, synaptic loss is a key pathological hallmark in Alzheimer’s disease, closely related to cognitive dysfunction and...

    Greet Vanderlinden, Jenny Ceccarini, ... Koen Van Laere in Molecular Psychiatry

    Article 06 July 2022
    

17. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [¹⁸F]SDM-16

    Purpose

    To quantify the synaptic vesicle glycoprotein 2A (SV2A) changes in the whole central nervous system (CNS) under pathophysiological conditions,...

    Chao Zheng, Daniel Holden, ... Zhengxin Cai in European Journal of Nuclear Medicine and Molecular Imaging

    Article Open access 11 November 2021
    

18. Preliminary evidence for preserved synaptic density in late-life depression

    Late-life depression has been consistently associated with lower gray matter volume, the origin of which remains largely unexplained. Recent in-vivo...

    Thomas Vande Casteele, Maarten Laroy, ... Mathieu Vandenbulcke in Translational Psychiatry

    Article Open access 14 March 2024
    

19. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain

    The discovery of ketamine as a rapid and robust antidepressant marks the beginning of a new era in the treatment of psychiatric disorders. Ketamine...

    Sophie E. Holmes, Sjoerd J. Finnema, ... Irina Esterlis in Molecular Psychiatry

    Article 15 February 2022
    

20. Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET)

    Purpose

    Exploring synaptic density changes during brain growth is crucial to understanding brain development. Previous studies in nonhuman primates...

    Samantha Rossano, Takuya Toyonaga, ... Richard E. Carson in European Journal of Nuclear Medicine and Molecular Imaging

    Article 28 May 2022